Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for OUD with Comorbid Depression
NCT05051449Phase 1Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by University of Maryland, Baltimore. Primary endpoints: Feasibility: Study Recruitment at 1 year, Feasibility: Study Retention at 1 year and 2 more. Started Apr 2022; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05051449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05051449.